3. Lankaputhra WEV, Shah NP: Surv iva l o f L a c t o b a c i l l u s a c i d o p h i l u s a n d Bifidobacterium ssp. in the presence of acid and bile salts. Cult Dairy Prod J 1995; 30: 2–7.
4. Shanahan F, Coll ins SM: Pharmabiot ic m a n i p u l a t i o n o f t h e m i c r o b i o t a i n gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am 2010; 39: 721–26.
5. N g S C , H a r t A L , K a m m M A , e t a l : Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 300–10.
6. Rousseaux C, Thuru X, Gelot A, et a l : L a c t o b a c i l l u s a c i d o p h i l u s m o d u l a t e s in tes t inal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35–7.
7. Kau AL, Ahern PP, Griffin NW, et al: Human nut r i t ion , the gut microbiome and the immune system. Nature 2011; 474: 327–36.
8. Hwang EN, Kang SM, Kim MJ, e t a l : Screening of Immune-Active Lactic Acid Bacteria. Korean J Food Sci Anim Resour 2015; 35(4): 541-50.
9. Macpherson AJ, Harris NL: Interactions between commensal intestinal bacteria and
the immune system. Nat Rev Immunol 2004; 4: 478–85.
10. Madsen KL: Interactions between microbes and the gut epithelium. J Clin Gastroenterol 2011; 45(Suppl): S111–114.
11. Besselink MG, van Santvoort HC, Buskens E, et al: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-bl ind, placebo-control led t r ia l Lancet 2008; 371: 651–9.
12. Boyle RJ, Robins-Browne RM, Tang ML: Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83: 1256–64.
13. Goran H, Nermin S , Kar ina V, e t a l : Probiotics for Standard Triple Helicobacter pylori Eradication A Randomized, Double-blind, Placebo-controlled Trial. Medicine (Baltimore) 2015; 94(17): e685.
14. Clarke G, Cryan JF, Dinan TG, e t a l : Review article: probiotics for the treatment of irritable bowel syndrome - focus on lactic acid bacteria. Aliment Pharmacol Ther 2012; 35(4): 403-13.
15. Moraes-Filho JP, Quigley EM: The intestinal microbiota and the role of probiotics in irritable bowel syndrome: a review. Arq Gastroenterol 2015; 52(4): 331-8.
16. Wi l l i a m s M D , H a C Y, C i o r b a M A : Probiotics as therapy in gastroenterology:
2016 60 6 39
a s t u d y o f p h y s i c i a n o p i n i o n s a n d recommendations. J Clin Gastroenterol 2010; 44: 631–6.
17. Bajaj JS, Saeian K, Christensen KM, et al: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008; 103: 1707–15.
18. Hempel S, Newberry S, Ruelaz A, et al: Services USDoHaH. Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. 2011.
19. Snydman DR: The safety of probiotics. Clin Infect Dis 2008; 46(Suppl 2): S104–111.
20. Shanahan F: Probiotics in perspective. Gastroenterology 2010; 139: 1808–12.
![Elsevier Masson - All titles · 2021. 1. 5. · /^ E d/d> hd,KZ K>> d/KE õ ó ô î î õ ð ó ñ ð î ó î } o v Ç Z } Z } o } P ] r õ õ ó ô î î õ ð ó ñ ð ð ò ï](https://static.documents.pub/doc/80x56/60ce5dc8e5eb0d169d706d8c/elsevier-masson-all-titles-2021-1-5-e-dd-hdkz-k-dke-.jpg)
![v Z ] oD } } & µ o o ] Z u v ñ l ñ l î ì î ì - Michigan · >> ' e ð õ ì í ì z > z ð õ ï í í kzz ð õ ï î ï kzz ð õ ï î ï kzz ð õ ï î ï kzz ð õ ï](https://static.documents.pub/doc/80x56/5fabf8bd5d48da0134177360/v-z-od-o-o-z-u-v-l-l-michigan-e.jpg)
![·Û - Johnny Roger's | BBQ & Burgers | Concord, NC Menu 1.1... · A·\QVWSaÛ Z ] o ] Z && ò X ð õ D ] v ] } v } P ð X õ õ } v Z && ò X ð õ K v ] } v Z ] v P l ð X õ õ](https://static.documents.pub/doc/80x56/5fc183d7f6497807b2556b71/-johnny-rogers-bbq-burgers-concord-nc-menu-11-aqvwsa-z.jpg)
![õ ] ¢ B6 Ú C333R(]0]Q]:]+] ~ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾ ¾](https://static.documents.pub/doc/80x56/611c7debf287c935f0294187/-b6-c-333r0q-.jpg)
